In this report, we synthesized folic acid-modified laponite (LAP) nanodisks as a targeted drug delivery system for efficient loading and delivery of anticancer drug doxorubicin (DOX) to cancer cells overexpressing folate receptors (FR). The surface modification of LAP was successfully accomplished through step-by-step coupling reactions with 3-aminopropyldimethylethoxysilane and then folic acid by the aid of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide. The formed folic acid-modified LAP (LM-FA) was characterized by UV-Vis spectroscopy and thermogravimetric analysis, and used as a carrier to encapsulate and release DOX. We show that DOX is able to be encapsulated within the interlayer space of LAP with a high loading efficiency of 92.1% and be released at a quicker rate at acidic pH condition (pH = 5.4) than at physiological pH condition. The specific therapeutic efficacy of LM-FA/DOX to FR-overexpressed cancer cells will be demonstrated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell viability assay and laser scanning confocal microscopy observation in future work. Therefore, cancer-cell-specific ligand modified laponite may be used as drug carriers to encapsulate cancer drugs for potential targeting therapy of different types of cancer.

Folic acid-modified laponite nanodisks as targeted carriers for doxorubicin delivery

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.